Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New nerve graft could spare patients a second surgery

NCT ID NCT07657182

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a processed nerve graft from a donor (Avance Nerve Graft) works as well as using a piece of the patient's own leg nerve to repair damaged nerves in the arm. About 178 adults with upper arm nerve injuries will be randomly assigned to receive either the donor graft or their own nerve. The main goal is to see how well motor and sensory function recovers over two years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Avance Nerve Graft (a processed human nerve scaffold)
What this could lead to
If successful, this could offer a safe and effective alternative to using a patient's own nerve for repair, avoiding the need for a second surgery and loss of function at the donor site.
What could go wrong
This is a relatively early-phase study with 178 participants, so results may not apply to all nerve injuries. The Avance graft may not perform as well as the patient's own nerve in restoring full function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 178 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Study Participant Criteria 1. Be ≥ 18 years of age at the time of consent; 2. Willing and able to comply with all aspects of the treatment and evaluation schedule over a 24-month duration; 3. Provide documented Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved informed consent prior to initiation of any study procedures; Injury/Repair Criteria for Each Nerve 4. Primary or secondary nerve injury repair with sural nerve autograft or Avance Nerve Graft for fully transected reconstruction of the following upper extremity mixed and/or motor nerve(s): * Median nerve: proximal nerve stump within 20 cm from the center point of the thenar eminence and distal to the crease of the elbow; * Anterior interosseous nerve; * Median nerve recurrent motor branch; * Radial nerve: proximal nerve stump within 20 cm of the center of the forearm (midpoint between the tip of the olecranon and the styloid process) and distal to the mid-humerus; * Posterior interosseous nerve. 5. Zone of injury of eligible nerve(s) resectable to healthy nerve both distally and proximally and within the anatomical regions of Inclusion Criterion #4; 6. In study participants with multiple eligible nerve repairs, repair of all eligible nerves completed with the same study treatment, either Avance Nerve Graft or sural nerve autograft; 7. Measured nerve gap(s) following resection \> 25 mm; 8. Nerve(s) repaired ≤ 120 days post injury; 9. Undergo coaptation on both the proximal and distal portion of the nerve gap(s) per the USPI for Avance Nerve Graft and per standard of care for sural nerve autograft; and 10. Either treatment method, Avance Nerve Graft or sural nerve autograft, is a viable option for all eligible nerve repair(s) (i.e., volume of injured nerve\[s\] does not exceed availability of sural nerve autograft for reconstruction, study participants are not treated with a combination of treatment types). Exclusion Criteria: Study Participant Criteria 1. Currently enrolled in another clinical study that may interfere with treatment, assessment of recovery, or participation in this study; 2. Deformities or injuries of the limb, hand, or digits that affect both the primary and secondary assessments for eligible nerve repair(s); 3. History of neuropathy of any etiology, diabetic neuropathy or any other known neuropathy including compressive/traumatic neuropathies affecting the target limb; 4. History of progressive neurodegenerative or autoimmune disorder affecting peripheral nerve or motor function (e.g., amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease); 5. History of chronic ischemic condition of the upper extremity; 6. Expected use of medication during the study that is known to impact nerve regeneration or to cause peripheral neuropathy; 7. Undergoing or expected to undergo treatment with chemotherapy, radiation therapy, or other known treatment which affects the growth of neural and/or vascular systems; 8. Participant is unlikely to comply with all study requirements and standard medical care procedures for the duration of the study schedule; Injury/Repair Criteria for Each Nerve 9. Median nerve repairs where the ulnar nerve has been transected due to injury or repair; 10. Repair(s) of a sensory-only proximal nerve stump; 11. Incomplete nerve transections; 12. Multilevel nerve injury pattern requiring two or more isolated reconstructions along the nerve pathway (for example, reconstruction of median nerve in forearm and recurrent motor branch resulting in repair pattern of graft to native nerve to graft to distal target); 13. Inadequate soft tissue coverage or extensive soft tissue injury which will impair recovery assessment; 14. Nerve avulsion injuries and nerve traction injuries resulting in rupture of the nerve; 15. Replantation/amputation of the limb, hand, or digits involved in both the primary and secondary assessments for eligible nerve repair(s); 16. Nerve repairs utilizing either end-to-side or side-to-side coaptation techniques; 17. Nerve transfer, tendon transfer, or other concomitant treatment at the time of nerve repair that affects assessment of function of the innervated muscle organ; 18. Use of coaptation devices that include metallic components or activated polymers and coaptations completed with fibrin glue only; and 19. Injuries with vascular damage resulting in inadequate perfusion despite repair (i.e., both radial and ulnar arteries injured \[one injured artery is allowed\]).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mixed peripheral nerve injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Peripheral Nerve Injuries traumatic neuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • OrthoIndy

    RECRUITING

    Indianapolis, Indiana, 46260, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.